← Back to Search

LY3540378 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 through day 113
Awards & highlights

Study Summary

This study is evaluating whether a drug may be safe and effective for treating cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 through day 113
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 through day 113 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3540378
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3540378

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3540378 (Part D)Experimental Treatment1 Intervention
Multiple ascending doses of LY3540378 administered SC in Chinese Participants.
Group II: LY3540378 (Part C)Experimental Treatment1 Intervention
Multiple ascending doses of LY3540378 administered SC in Japanese Participants.
Group III: LY3540378 (Part B)Experimental Treatment1 Intervention
Multiple ascending doses of LY3540378 administered SC.
Group IV: LY3540378 (Part A)Experimental Treatment1 Intervention
Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC).
Group V: Placebo (Part A, B, C & D)Placebo Group1 Intervention
Placebo administered either IV or SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3540378
2021
Completed Phase 1
~140

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,627 Previous Clinical Trials
3,217,739 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,351 Previous Clinical Trials
416,342 Total Patients Enrolled
~32 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top